MA38488A1 - Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate - Google Patents

Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate

Info

Publication number
MA38488A1
MA38488A1 MA38488A MA38488A MA38488A1 MA 38488 A1 MA38488 A1 MA 38488A1 MA 38488 A MA38488 A MA 38488A MA 38488 A MA38488 A MA 38488A MA 38488 A1 MA38488 A1 MA 38488A1
Authority
MA
Morocco
Prior art keywords
quinuclidin
thiazol
propan
fluorophenyl
forms
Prior art date
Application number
MA38488A
Other languages
English (en)
Inventor
Craig Siegel
Jin Zhao
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50543351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA38488A1 publication Critical patent/MA38488A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne de nouvelles formes de sels de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate utiles en tant qu'un inhibiteur de synthase de glucosylcéramide (gcs) et pour le traitement de maladies métaboliques telles que les maladies lysosomales, soit seul, soit en association avec une thérapie de remplacement enzymatique, et pour le traitement du cancer.
MA38488A 2013-03-15 2014-03-14 Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate MA38488A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791706P 2013-03-15 2013-03-15
PCT/US2014/027081 WO2014152215A1 (fr) 2013-03-15 2014-03-14 Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate

Publications (1)

Publication Number Publication Date
MA38488A1 true MA38488A1 (fr) 2017-10-31

Family

ID=50543351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38488A MA38488A1 (fr) 2013-03-15 2014-03-14 Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate

Country Status (34)

Country Link
US (1) US9518049B2 (fr)
EP (1) EP2970250B1 (fr)
JP (1) JP6438455B2 (fr)
KR (1) KR102302064B1 (fr)
CN (1) CN105189490A (fr)
AR (1) AR095435A1 (fr)
AU (1) AU2014240028B2 (fr)
BR (1) BR112015022907B1 (fr)
CA (1) CA2906691A1 (fr)
CL (1) CL2015002701A1 (fr)
DK (1) DK2970250T3 (fr)
EA (1) EA037527B1 (fr)
ES (1) ES2872326T3 (fr)
HK (1) HK1214821A1 (fr)
HR (1) HRP20210692T1 (fr)
HU (1) HUE054349T2 (fr)
IL (1) IL241229B (fr)
JO (1) JO3713B1 (fr)
LT (1) LT2970250T (fr)
MA (1) MA38488A1 (fr)
MX (1) MX370178B (fr)
MY (1) MY181766A (fr)
PH (1) PH12015502021A1 (fr)
PL (1) PL2970250T3 (fr)
PT (1) PT2970250T (fr)
RS (1) RS61852B1 (fr)
SA (1) SA515361078B1 (fr)
SG (1) SG11201507054YA (fr)
SI (1) SI2970250T1 (fr)
TN (1) TN2015000427A1 (fr)
TW (1) TWI713438B (fr)
UY (1) UY35439A (fr)
WO (1) WO2014152215A1 (fr)
ZA (1) ZA201506602B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
WO2015089067A1 (fr) * 2013-12-11 2015-06-18 Genzyme Corporation Inhibiteurs de la glucosylcéramide synthase
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
JP2022519131A (ja) 2019-02-04 2022-03-18 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置
IL295255A (en) * 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
CA3186766A1 (fr) 2020-07-24 2022-01-27 Danielle Combessis Compositions pharmaceutiques comprenant du venglustat
JP2023535483A (ja) 2020-07-30 2023-08-17 ジェンザイム・コーポレーション 脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法
WO2022215083A1 (fr) * 2021-04-05 2022-10-13 Msn Laboratories Private Limited, R&D Center Formes à l'état solide de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl) carbamate ou de sels et procédé de préparation associé
WO2024116127A1 (fr) 2022-12-01 2024-06-06 Genzyme Corporation Venglustat en combinaison avec un inhibiteur fort ou modéré de cyp3a4

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP2147681A1 (fr) 1997-10-29 2010-01-27 Genzyme Corporation Compositions et méthodes pour le traitement de maladies lysosomales
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
WO2010091104A1 (fr) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibiteurs de la glucosylcéramide synthase
KR20230164773A (ko) 2009-08-28 2023-12-04 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
RU2645675C2 (ru) * 2011-03-18 2018-02-27 Джензим Корпорейшн Ингибиторы глюкозилцерамид-синтазы

Also Published As

Publication number Publication date
MX2015012295A (es) 2016-05-16
LT2970250T (lt) 2021-05-10
US9518049B2 (en) 2016-12-13
BR112015022907A2 (pt) 2017-07-18
JP2016513679A (ja) 2016-05-16
SA515361078B1 (ar) 2018-06-14
EA201591706A1 (ru) 2016-02-29
NZ712659A (en) 2020-11-27
AU2014240028A1 (en) 2015-10-15
WO2014152215A1 (fr) 2014-09-25
EP2970250A1 (fr) 2016-01-20
UY35439A (es) 2014-10-31
ZA201506602B (en) 2023-04-26
US20160039805A1 (en) 2016-02-11
DK2970250T3 (da) 2021-07-12
IL241229A0 (en) 2015-11-30
PH12015502021A1 (en) 2016-01-11
KR20150132333A (ko) 2015-11-25
PT2970250T (pt) 2021-05-07
CN105189490A (zh) 2015-12-23
JO3713B1 (ar) 2021-01-31
CL2015002701A1 (es) 2016-03-18
MX370178B (es) 2019-12-04
BR112015022907A8 (pt) 2019-11-26
AU2014240028B2 (en) 2018-08-02
HK1214821A1 (zh) 2016-08-05
TW201502127A (zh) 2015-01-16
SG11201507054YA (en) 2015-10-29
IL241229B (en) 2019-12-31
BR112015022907B1 (pt) 2022-07-12
RS61852B1 (sr) 2021-06-30
MY181766A (en) 2021-01-06
JP6438455B2 (ja) 2018-12-12
KR102302064B1 (ko) 2021-09-13
PL2970250T3 (pl) 2021-12-06
AR095435A1 (es) 2015-10-14
HUE054349T2 (hu) 2021-09-28
EP2970250B1 (fr) 2021-04-21
HRP20210692T1 (hr) 2021-06-11
EA037527B1 (ru) 2021-04-08
CA2906691A1 (fr) 2014-09-25
TN2015000427A1 (en) 2017-01-03
TWI713438B (zh) 2020-12-21
SI2970250T1 (sl) 2021-06-30
ES2872326T3 (es) 2021-11-02

Similar Documents

Publication Publication Date Title
MA38488A1 (fr) Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate
MA35023B1 (fr) Inhibiteurs de la glucosylcéramide synthase
MA37975B2 (fr) Inhibiteurs de synthase de glucosylcéramide
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
CL2015003731A1 (es) Inhibidores de bromodominios
EA201790398A1 (ru) Способы лечения заболевания печени
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
EA201791993A1 (ru) Способы лечения протеинопатий
MX2018008299A (es) Metodos para administrar hepcidina.
SG10201804952QA (en) Glucosylceramide synthase inhibitors
MX2018002263A (es) Potenciador de atp intracelular.
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MX2024000805A (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.
MX2019014306A (es) Agente para reducir la cantidad de proteina beta amiloide.
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
PH12019501358A1 (en) Methods of administering hepcidin
MA44634A1 (fr) Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate
EA201790642A1 (ru) Аллель-специфическая терапия для гаплотипов болезни хантингтона
NZ702645A (en) A method of improving liver function
MX2017000184A (es) Agentes de interaccion enzimatica.